ImaginAb announces extension of long-standing partnership with Boehringer Ingelheim

ImaginAb announces extension of long-standing partnership with Boehringer Ingelheim

New license and supply agreement will see ImaginAb supply Boehringer Ingelheim with its market leading CD8 ImmunoPET technology

ImaginAb Inc, a market leading global biotechnology company, focused on developing next generation immuno oncology imaging agents and therapeutic radiopharmaceuticals (RPT), today announced the signing of a new significant multi-year, non-exclusive license agreement with Boehringer Ingelheim.

The agreement, which builds on the long-term collaboration between the two companies that started in 2017 will see ImaginAb supply clinical doses of its market leading 89Zr CD8 ImmunoPET technology to Boehringer Ingelheim for use in the clinical development of its novel oncology therapeutics throughout North America and Europe.

ImaginAb will receive license fees and payments for providing ongoing technical, clinical, and regulatory support to enable the successful implementation of its CD8 ImmunoPET technology. No other terms were disclosed.

Commenting on the announcement, Ian Wilson, Chief Executive Officer of ImaginAb stated:

“Boehringer Ingelheim, were the first to partner with us on our CD8 ImmunoPET agent, and we are delighted we can expand our partnership and enable our technology to be used across multiple clinical programs. 

“ImaginAb has a clear aim to become the lead in diagnostic and treatment choices, transforming patient care and helping patients live better and healthier lives. Our CD8 ImmunoPET technology enables quicker identification of drug efficacy, potentially reduce the length of trials and allowing new therapies to advance to market quicker. It also removes the need for repeat, painful biopsies. All of which will ultimately transform patient care.

“This announcement is just the latest in a number of new non-exclusive license agreements that we have announced this year. It is a clear indication that not only is our technology gaining wider acceptance, but many others also share our vision, and belief in the benefits that our CD8 ImmunoPET technology offers.”

Related News